Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Pelage Pharmaceuticals","sponsor":"Main Street Advisors","pharmaFlowCategory":"D","amount":"$16.7 million","upfrontCash":"Undisclosed","newsHeadline":"Pelage Pharmaceuticals Announces $16.75M Series A Financing led by GV to Revolutionize Regenerative Medicine for Hair Loss","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Pelage Pharmaceuticals

    Menu

    Pelage Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Pelage Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Pelage Pharmaceuticals Announces $16.75M Series A Financing led by GV to Revolutionize Regenerative Medicine for Hair Loss

              Details:

              The financing aims to support the clinical development of PP405, a novel topical agent, which is designed to treat androgenetic alopecia and and other forms of hair loss.

              Lead Product(s): PP405

              Therapeutic Area: Dermatology Product Name: PP405

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Main Street Advisors

              Deal Size: $16.7 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing February 27, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY